Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


For OTC And Supplement Success Stories, Firms Need Multiple Writers

This article was originally published in The Tan Sheet

Executive Summary

Gaining market share in the increasingly competitive and regulated OTC and supplement sectors requires a collaborative approach with R&D, legal and marketing teams working together from the start, says Novartis Consumer executive Rosanne Rotondo.

You may also be interested in...

Sodium phosphate drugs

Rectal products containing sodium phosphate/sodium biphosphate would be required to bear sodium content and warning statements under a proposed rule published by FDA in the March 24 Federal Register. The proposal would apply the same requirements to rectal sodium phosphate drugs that now apply to other OTCs containing sodium. The action responds to concerns that individuals with certain medical conditions are at risk of an electrolyte imbalance when using such products. Comments are requested by June 22...

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Ensuring Leading Position For GSK Consumer Products Touted In Management Shift

GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts